| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The molecular targets of Ardisiacrispin A are not fully defined but are believed to involve the modulation of various signaling pathways. Its cytotoxic activity is associated with the induction of apoptosis and the disassembly of microtubules. The compound's ability to inhibit the cytopathic effects of poliovirus and HSV-1 suggests that it may target viral replication or entry. Its immunomodulatory effects may involve the modulation of immune cell function. Further studies are needed to identify its precise molecular targets and mechanisms of action. The compound's diverse biological activities make it a promising lead for drug development.
|
|---|---|
| ln Vitro |
In vitro, Ardisiacrispin A exhibits potent cytotoxic activity against various cancer cell lines. It has a GI50 value of 1.56 microM against HepG2 cancer cells. It inhibits the proliferation of Bel-7402 cells by inducing apoptosis and disassembling microtubules. The compound also inhibits the cytopathic effects of poliovirus type I and herpes simplex virus 1 (HSV-1) in filter paper disk assays. Its immunomodulatory effects include modulation of immune cell function. These in vitro activities are concentration-dependent and have been observed at micromolar concentrations. Ardisiacrispin A is a valuable tool for studying the biological activities of triterpenoid saponins.
|
| ln Vivo |
In vivo, Ardisiacrispin A has potential applications in cancer therapy and antiviral treatment. Its in vitro cytotoxic activity against cancer cells suggests that it may have antitumor activity in vivo. Its antiviral activity against poliovirus and HSV-1 indicates potential for treating viral infections. However, in vivo studies are limited, and further research is needed to evaluate its efficacy, pharmacokinetics, and safety in animal models. The compound's natural origin and diverse biological activities make it a promising candidate for further development.
|
| Enzyme Assay |
The in vitro cytotoxic activity of Ardisiacrispin A can be assessed using cell-free or cell-based assays. For cell-free assays, the compound's ability to disassemble microtubules can be assessed using purified tubulin and measuring tubulin polymerization by turbidity. For antiviral activity, cell-free assays can be used to assess the compound's ability to inhibit viral enzymes, such as viral proteases or polymerases. However, most studies on Ardisiacrispin A have used cell-based assays to assess its biological activity.
|
| Cell Assay |
For in vitro cellular experiments, cancer cell lines (e.g., HepG2, Bel-7402) are cultured in appropriate media and treated with Ardisiacrispin A at various concentrations (typically 0.1-100 microM). Cell viability is measured after 24-72 hours of treatment using MTT, CCK-8, or other cell proliferation assays. Apoptosis is assessed by flow cytometry using Annexin V/PI staining or by measuring caspase-3/7 activity. Microtubule integrity is assessed by immunostaining for alpha-tubulin or beta-tubulin. For antiviral studies, virus-permissive cells are infected with poliovirus or HSV-1 and treated with the compound, and viral replication is assessed by measuring viral titers or cytopathic effects.
|
| Animal Protocol |
In vivo animal experiments with Ardisiacrispin A are not well-documented in the available literature. However, given its in vitro anticancer and antiviral activities, it could be evaluated in xenograft mouse models or viral infection models. A typical study would involve administering the compound via intraperitoneal or oral administration to tumor-bearing or virus-infected animals. Tumor growth, viral load, and survival would be monitored. Pharmacokinetic and toxicity studies would also be required to determine the optimal dosing regimen and safety profile. Further preclinical studies are needed to fully characterize its in vivo activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ardisiacrispin A are not well-documented in the available literature. As a triterpenoid saponin with a molecular weight of 1061.23 g/mol and a molecular formula of C52H84O22, it is a large, polar molecule that is likely to have poor oral bioavailability. The compound may be administered by injection in preclinical studies. Its absorption, distribution, metabolism, and excretion properties would need to be characterized to support its development as a therapeutic agent. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Ardisiacrispin A has not been extensively characterized. As a natural product with cytotoxic activity, it may have potential toxicity to normal cells. Its ability to disassemble microtubules and induce apoptosis could lead to toxicity in rapidly dividing tissues. In vitro cytotoxicity studies would be needed to assess its effects on normal cell lines. In vivo toxicity studies in animal models would also be required to determine its safety profile. The compound should be handled with standard laboratory precautions and is intended for research use only.
|
| References | |
| Additional Infomation |
Ardisiacrispin A has been reported to be found in marigolds, pearlwort, and other organisms with available data.
Ardisiacrispin A is a triterpenoid saponin isolated from Ardisia species. It exhibits cytotoxic activity against HepG2 cancer cells with a GI50 of 1.56 microM and inhibits the proliferation of Bel-7402 cells by inducing apoptosis and disassembling microtubules. It also inhibits the cytopathic effects of poliovirus type I and herpes simplex virus 1 (HSV-1). Ardisiacrispin A has immunomodulatory effects. It is a valuable tool for studying the biological activities of triterpenoid saponins. The compound is available as a research compound and is not approved for clinical use. |
| Molecular Formula |
C52H84O22
|
|---|---|
| Molecular Weight |
1061.2102
|
| Exact Mass |
1060.545
|
| CAS # |
23643-61-0
|
| PubChem CID |
10328746
|
| Appearance |
White to off-white solid powder
|
| Density |
1.48±0.1 g/cm3 (20 ºC 760 Torr)
|
| Index of Refraction |
1.635
|
| LogP |
3.78
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
74
|
| Complexity |
2020
|
| Defined Atom Stereocenter Count |
29
|
| SMILES |
C[C@@]1(CC[C@@]23CO[C@]4([C@@H]2C1)CC[C@@H]5[C@]6(CC[C@@H](C([C@@H]6CC[C@]5([C@@]4(C[C@H]3O)C)C)(C)C)O[C@H]7[C@@H]([C@H]([C@H](CO7)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)C)C=O
|
| InChi Key |
JXTOWLUQSHIIDP-VKKSEJOZSA-N
|
| InChi Code |
InChI=1S/C52H84O22/c1-46(2)27-7-11-49(5)28(8-12-52-29-15-47(3,21-55)13-14-51(29,22-68-52)30(57)16-50(49,52)6)48(27,4)10-9-31(46)72-44-40(74-43-39(65)36(62)33(59)24(17-53)69-43)35(61)26(20-67-44)71-45-41(37(63)34(60)25(18-54)70-45)73-42-38(64)32(58)23(56)19-66-42/h21,23-45,53-54,56-65H,7-20,22H2,1-6H3/t23-,24-,25-,26+,27+,28-,29-,30-,31+,32+,33-,34-,35+,36+,37+,38-,39-,40-,41-,42+,43+,44+,45+,47+,48+,49-,50+,51-,52+/m1/s1
|
| Chemical Name |
(1S,2R,4S,5R,8R,10S,13R,14R,17S,18R,20S)-10-[(2S,3R,4S,5S)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-hydroxy-4,5,9,9,13,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracosane-20-carbaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~94.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9423 mL | 4.7116 mL | 9.4232 mL | |
| 5 mM | 0.1885 mL | 0.9423 mL | 1.8846 mL | |
| 10 mM | 0.0942 mL | 0.4712 mL | 0.9423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
